Outcomes of pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls.
BACKGROUND
Due to the profound shortage of suitable deceased allografts, much effort has been made to investigate whether successful kidney transplantation (KT) is possible across the ABO blood group barrier even for pediatric recipients.


METHODS
We reviewed 52 consecutive ABO incompatible (ABOic) transplantation performed between September 1989 and March 2011. The mean age at transplantation was 10.6 ± 3.9 years (range, 4.4-19.7), with 35 boys and 17 girls. The donor-to-recipient ABO blood antigen incompatibility was as follows: A1/O (n = 17); B/O (n = 13); A1/B (n = 6); B/A1 (n = 1); A1B/B (n = 9); and A1B/A (n = 6). As a control group, data were collected from 271 pediatric ABO compatible (ABOc) living donor KT in the same period.


RESULTS
Overall acute rejection episodes (ARE) among the ABOic group were significantly higher than those of the ABOc group (44% vs 26%; P < .02). However, there was no difference in glomerular filtration rate (GFR) at 1 year after transplantation: 86 ± 31 mL/min for ABOic vs 99 ± 37 mL/min for ABOic, respectively. The 1-y, 5-y, and 10-year patient survival rates were 98%, 92%, and 92% in the ABOic group, respectively, and 99%, 98%, and 97% in the ABOc group, respectively (P = not significant [NS]). The overall 1-, 5-, 10-, and 15-year graft survival rates were 94%, 88%, 86%, and 86% in the ABOic group, respectively, and 95%, 92%, 88%, and 78% in the ABOc group, respectively.


CONCLUSIONS
ABOic KT provided long-term allograft and patient survivals equivalent to ABOc live donor transplantations.
Department of Pediatric Nephrology, Toho University, Tokyo, Japan.
S
S
Shishido
Y Y
YY
Hyodo
Y
Y
Aoki
J
J
Takasu
T
T
Kawamura
K K
KK
Sakai
A A
AA
Aikawa
H
H
Satou
M M
MM
Muramatsu
Z
Z
Matsui
D000017:ABO Blood-Group System / Q000276:immunology*; D000293:Adolescent; D000367:Age Factors; D001787:Blood Group Incompatibility / Q000276:immunology*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000821:virology; D003888:Desensitization, Immunologic / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival; D006648:Histocompatibility; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D019520:Living Donors; D008297:Male; D010956:Plasmapheresis / Q000009:adverse effects; D018570:Risk Assessment; D012307:Risk Factors; D013156:Splenectomy / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D000017:ABO Blood-Group System; D007166:Immunosuppressive Agents